Chemtos Applies to Bulk Manufacture Controlled Substances
Published Date: 3/30/2026
Notice
Summary
Chemtos, LLC wants to become a big-time maker of certain controlled substances, including some strong and tightly regulated drugs. People and companies involved with these substances can share their thoughts or ask for a hearing by May 29, 2026. This move could shake up the supply chain and means Chemtos is stepping into a serious role with important deadlines and rules to follow.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Deadline to Comment or Request Hearing
Registered bulk manufacturers of the affected basic classes and applicants may submit electronic comments or objections, or request a hearing, on or before May 29, 2026. Comments must be submitted through https://www.regulations.gov and you will receive a Comment Tracking Number when your submission is accepted.
Application to Manufacture Schedule I Reference Standards
On February 13, 2026, Chemtos, LLC (Round Rock, Texas) applied to be registered as a bulk manufacturer of multiple Schedule I controlled substances, including 4-Chloromethcathinone (drug code 1239) and others listed in the notice. The company plans to bulk manufacture the listed substances for distribution as reference standards to its customers, and no other activities for these drug codes are authorized under this registration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13705 — Importer of Controlled Substances Application: Benuvia Operations, LLC.
Benuvia Operations, LLC wants to become an official importer of certain controlled substances like marijuana extract and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 6, 2026. This move could shake up who gets to bring these substances into the U.S., so keep an eye on the deadline if you’re interested!
2026-13581 — Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
2026-13580 — Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
2026-13364 — Schedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
Starting July 1, 2026, the DEA is temporarily putting four new substances—5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move helps keep these potentially dangerous drugs off the streets while the DEA studies them further.
Previous / Next Documents
Previous: 2026-06051 — Importer of Controlled Substances Application: Usona Institute
Usona Institute wants to become an official importer of some powerful controlled substances like mescaline and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by April 29, 2026. This move could impact research and medical use, with no direct cost changes announced yet.
Next: 2026-06053 — Importer of Controlled Substances Application: Pharmaron Manufacturing Services (US) LLC
Pharmaron Manufacturing Services (US) LLC wants to become an official importer of certain controlled substances, like poppy straw concentrate. This means they’ll be allowed to bring these drugs into the U.S. Companies and manufacturers affected have until April 29, 2026, to share their thoughts or ask for a hearing. No direct money changes yet, but this could impact drug supply chains soon!